Survival in heart failure
Introduction
- Heart failure (HF) is an enormous public health burden with 300,000 new deaths each year and a prevalence of 6.5 million people in the United States1.
- There is large variability in HF prognosis2, and there is a need for a broader systemic approach to identify novel circulating markers of HF progression.
- One of the most robust and validated models for mortality prediction in HF patients is the Meta-Analysis Global Group in Chronic Heart Failure (MAGGIC) Score3.
- Additionally, the use of N-Terminal pro-B-Type Natriuretic Peptide (NTproBNP) has been shown to be valuable in prognosis prediction4.
- It is uncertain if the plasma proteome is a better prediction tool for the course of HF compared to the clinical risk score MAGGIC and NTproBNP.
Learn more by downloading this poster
More posters
PosterComparison of Proteomic CV Risk to Established ASCVD 10-Year Risk Decision Points
The ASCVD pooled cohort equation (PCE) is well-established for CV risk assessment. Decision points for determining treatment plans are low, intermediate and high risk over 10 years, however this approach over and underestimates risk in certain subgroups. The validated CV Risk SomaSignal® Test (SST) provides 4-year risk probability of MACE allowing for timely assessment of risk, but the shorter timescale makes comparison to 10-year PCE risk less intuitive.
PosterStatin signature: using proteomics to detect pharmacological fingerprints
Using a previously described metacohort (n=5,575) of patients with increased CV risk, we hypothesized that PCE would stratify patients differently than the CV Risk SST, and that CV Risk score scaled to 10 years would yield an improved net reclassification index (NRI).
PosterUsing a proteomics-based cardiovascular risk test to identify systemic changes in a clinical trial of nonalcoholic fatty liver disease
Improvement in hepaKc inflammaKon, NAFLD acKvity score and fibrosis were associated with improved proteomic CV risk scores regardless of treatment provided.